Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Curis, Inc. - Common Stock (NQ:CRIS)

1.550 -0.030 (-1.90%)
Streaming Delayed Price Updated: 12:23 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Curis, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Curis (CRIS) Q2 Loss Narrows 66%
Via The Motley Fool
Earnings Scheduled For August 5, 2025
 
Via Benzinga
A Peek at Curis's Future Earnings
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Earnings Outlook For Curis
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Examining the Future: Curis's Earnings Outlook
 
Via Benzinga
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
Curis's Earnings: A Preview
 
Via Benzinga
Earnings Scheduled For March 31, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Preview: Curis's Earnings
 
Via Benzinga
Analyst Ratings for Curis
 
Via Benzinga
Expert Ratings for Curis
 
Via Benzinga
Earnings Scheduled For November 14, 2024
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
CRIS Stock Earnings: Curis Beats EPS, Misses Revenue for Q1 2024
CRIS stock results show that Curis beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Top 3 Health Care Stocks That May Collapse In Q2
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Genesco Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Harbor Custom Development, Inc. (NASDAQ: HCDI) rose 74.2% to $1.50 after surging 24% on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance. 
Via Benzinga
Vail Resorts, Carnival, Opera And Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session. Corcept Therapeutics Incorporated (NASDAQ: CORT) shares... 
Via Benzinga
Topics Stocks
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
Analyst Holds Steady On Curis As FDA Removes Partial Clinical Hold On Leukemia Study
Thursday, the FDA removed the partial clinical hold on Curis Inc's (NASDAQ: CRIS) TakeAim Leukemia Phase 1/2 study of emavusertib  
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.